Common Cold
110
5
6
88
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
29 trials with published results (26%)
Research Maturity
88 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.6%
4 terminated out of 110 trials
95.7%
+9.1% vs benchmark
41%
45 trials in Phase 3/4
33%
29 of 88 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 88 completed trials
Clinical Trials (110)
Stopping Upper Respiratory Infections and Flu in the Family: The Stuffy Trial
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
Post-market Clinical Follow-up Study of an Isotonic Saline Solution to Manage Nasal Congestion in Case of Flu Symptoms, Colds, Allergic Rhinitis and Rhinosinusitis in Infants and Toddlers
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness
Effectiveness of a Nasal Spray on Viral Respiratory Infections
Supporting Parents to Choose Wisely
Efficacy and Safety of Silfamin for Common Cold
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Effects of LP28 on Immunity Enhancement in the Elderly
A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
BАbykids Spray In Common Cold
Testing the Efficacy in Adults With Cold of HEalsea Rescue*
Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections
Commercially Available Cannabis Products for Immune Support